Overview

A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Status:
Completed

Trial end date:
2011-04-14

Target enrollment:

Participant gender:

Summary

The Purpose of this study is to assess the efficacy and safety of two strengths of the FF/GW642444 Inhalation Powder in subjects with chronic obstructive pulmonary disease (COPD)

Phase:

Phase 3

Details

Lead Sponsor:

GlaxoSmithKline

Treatments:

Fluticasone